ARTA
NAVB

A.R.T. Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

A.R.T. Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,276
Closed -$7K – 1921
2019
Q3 		$7K Buy
+10,276
New +$6.32K ﹤0.01% 1387
2017
Q1 		– Sell
-2,585
Closed -$32K – 1865
2016
Q4 		$32K Buy
+2,585
New +$41K ﹤0.01% 1231
2016
Q3 		– Sell
-9,891
Closed -$104K – 1419
2016
Q2 		$104K Buy
+9,891
New +$194K 0.01% 1201
2016
Q1 		– Sell
-2,359
Closed -$62K – 1801
2015
Q4 		$62K Buy
+2,359
New +$81.9K ﹤0.01% 1367

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

A.R.T. Advisors's NAVB Position: Q4 2019 in Review

A.R.T. Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2019, closing a stake of 10,276 shares — an estimated $7K sold.

A.R.T. Advisors first reported a position in NAVB in Q4 2015 and held it in 4 quarters. The position peaked at $104K in Q2 2016. 28 funds tracked by Wall St. Rank hold NAVB as of Q4 2019.

  • A.R.T. Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 10,276 Navidea Biopharmaceuticals Inc. shares in Q4 2019, an estimated $7K.
  • A.R.T. Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2015 and held it in 4 quarters.
  • A.R.T. Advisors's Navidea Biopharmaceuticals Inc. position peaked at $104K in Q2 2016.
  • 28 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.